1. Morales, E, Galindo, M, Trujillo, H, et al. Update on lupus nephritis: looking for a new vision. Nephron 2021; 145(1): 1–13.
Google Scholar | Crossref | Medline2. Tektonidou, MG, Dasgupta, A, Ward, MM. Risk of end-stage renal disease in patients with lupus nephritis, 1971-2015: a systematic review and bayesian meta-analysis: Esrd risk in lupus nephritis. Arthritis Rheumatol 2016; 68(6): 1432–1441.
Google Scholar | Crossref | Medline3. Korbet, SM, Lewis, EJ, Schwartz, MM, et al. Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis; 35(5): 904–914.
Google Scholar | Crossref4. Sexton, DJ, Reule, S, Solid, C, et al. ESRD From Lupus Nephritis in the United States, 1995–2010. CJASN 2015; 10(2): 251–259.
Google Scholar | Crossref | Medline5. Bomback, AS . An update on therapies for proliferative lupus nephritis: how certain can we be about the evidence?. Am J Kidney Dis 2018; 72(5): 758–760.
Google Scholar | Crossref | Medline6. Parikh, SV, Almaani, S, Brodsky, S, et al. Update on Lupus Nephritis: Core Curriculum 2020. American Journal of Kidney Diseases, 2020, p. S0272638619311709.
Google Scholar7. Caster, DJ, Powell, DW. Utilization of Biomarkers in Lupus Nephritis. Adv Chronic Kidney Dis 2019; 26(5): 351–359.
Google Scholar | Crossref | Medline8. Stokes, MB, D’Agati, VD. Classification of lupus nephritis; time for a change?. Adv Chronic Kidney Dis; 26(5): 323–329.
Google Scholar | Crossref9. Terwee, CB, Jansma, EP, Riphagen, et al. Development of a methodological pubMed search filter for finding studies on measurement properties of measurement instruments. Qual Life Res 2009; 18(8): 1115–1123.
Google Scholar | Crossref | Medline10. Wells, GA, Shea, B, O’Connell, D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. The Ottawa hospital research institute, http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
Google Scholar11. Oxford Levels of Evidence. 2011. http://www.cebm.net/index.aspx?o=5653
Google Scholar12. Torres-Salido, MT, Cortés-Hernández, J, Vidal, X, et al. Neutrophil gelatinase-associated lipocalin as a biomarker for lupus nephritis. Nephrol Dial Transpl 2014; 29(9): 1740–1749.
Google Scholar | Crossref | Medline13. Go, DJ, Lee, JY, Kang, MJ, et al. Urinary vitamin D-binding protein, a novel biomarker for lupus nephritis, predicts the development of proteinuric flare. Lupus 2018; 27(10): 1600–1615.
Google Scholar | SAGE Journals | ISI14. Pesickova, SS, Rysava, R, Lenicek, M, et al. Prognostic value of anti-CRP antibodies in lupus nephritis in long-term follow-up. Arthritis Res Ther 2015; 17: 371.
Google Scholar | Crossref | Medline15. BASTURK, T, SARI, O, KOC, Y, et al. Prognostic Significance of NGAL in Early Stage Chronic Kidney Disease. Minerva Urologica e Nefrologica, 2017, http://www.minervamedica.it/index2.php?show=R19Y2017N03A0307.
Google Scholar | Crossref16. Tang, Y, Zhang, X, Ji, L, et al. Clinicopathological and outcome analysis of adult lupus nephritis patients in China. Int Urol Nephrol 2015; 47(3): 513–520.
Google Scholar | Crossref | Medline17. Kanno, A, Hotta, O, Yusa, N, et al. Predictive Factors of Clinical Outcome in Patients with Diffuse Proliferative Lupus Nephritis Treated Early by Intravenous Methylprednisolone Pulse Therapy. Ren Fail 2007; 29(1): 41–47.
Google Scholar | Crossref | Medline18. Ichinose, K, Kitamura, M, Sato, S, et al. Podocyte foot process width is a prediction marker for complete renal response at 6 and 12 months after induction therapy in lupus nephritis. Clin Immunol 2018; 197: 161–168.
Google Scholar | Crossref | Medline19. Erre, GL, Bosincu, L, Faedda, R, et al. Antiphospholipid syndrome nephropathy (APSN) in patients with lupus nephritis: a retrospective clinical and renal pathology study. Rheumatol Int 2014; 34(4): 535–541.
Google Scholar | Crossref | Medline20. Dall’Era, M, Levesque, V, Solomons, N, et al. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med 2015; 2(1): e000089.
Google Scholar | Crossref | Medline21. Cai, X, Yang, X, Lian, F, et al. Correlation between serum anti-C1q antibody levels and renal pathological characteristics and prognostic significance of anti-C1q antibody in lupus nephritis. J Rheumatol 2010; 37(4): 759–765.
Google Scholar | Crossref | Medline22. Kasitanon, N, Fine, DM, Haas, M, et al. Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 2006; 15(6): 366–370.
Google Scholar | SAGE Journals | ISI23. Pinto-Peñaranda, LF, Duque-Caballero, V, Márquez-Hernández, JD, et al. Predictive factors for low rate of remission in a population of Colombian patients with severe proliferative lupus nephritis. Clin Rheumatol 2015; 34(5): 897–903.
Google Scholar | Crossref | Medline24. Moroni, G, Radice, A, Giammarresi, G, et al. Are laboratory tests useful for monitoring the activity of lupus nephritis? A 6-year prospective study in a cohort of 228 patients with lupus nephritis. Ann Rheum Dis 2009; 68(2): 234–237.
Google Scholar | Crossref | Medline25. Barber, C, Herzenberg, A, Aghdassi, E, et al. Evaluation of clinical outcomes and renal vascular pathology among patients with lupus. Clin J Am Soc Nephrol 2012; 7(5): 757–764.
Google Scholar | Crossref | Medline26. Huang, J, Han, S, Qin, D, et al. Renal interstitial arteriosclerotic lesions in lupus nephritis patients: a cohort study from China. PLoS One 2015; 10(11): e0141547.
Google Scholar | Crossref | Medline27. Fanouriakis, A, Kostopoulou, M, Cheema, K, et al. Update of the joint European League against rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 20192020; 79(6): 713–723.
Google Scholar | Crossref | Medline28. Moroni, G, Gallelli, B, Quaglini, S, et al. Withdrawal of therapy in patients with proliferative lupus nephritis: long-term follow-up. Nephrol Dial Transpl 2006; 21(6): 1541–1548.
Google Scholar | Crossref | Medline29. Franco, C1, Yoo, W, Franco, D, et al. Predictors of end stage renal disease in African Americans with lupus nephritis. Bull NYU Hosp Jt Dis 2010; 68(4): 251–256.
Google Scholar | Medline30. Hernandez-Molina, G, García-Trejo, LP, Uribe, N, et al. Thrombotic microangiopathy and poor renal outcome in lupus patients with or without antiphospholipid syndrome. Clin Exp Rheumatol 2015; 33(4): 503–508.
Google Scholar | Medline31. Faurschou, M, Starklint, H, Halberg, P, et al. Prognostic factors in lupus nephritis: diagnostic and therapeutic delay increases the risk of terminal renal failure. J Rheumatol 2006; 33(8): 1563–1569.
Google Scholar | Medline32. Alsuwaida, A . Interstitial inflammation and long-term renal outcomes in lupus nephritis. Lupus 2013; 22(14): 1446–1454.
Google Scholar | SAGE Journals | ISI33. Yang, X, Tan, Y, Yu, F, et al. Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transpl 2012; 27(9): 3552–3559.
Google Scholar | Crossref | Medline34. Bajema, IM, Wilhelmus, S, Alpers, CE, et al. Revision of the international society of nephrology/renal pathology society classification for lupus nephritis: clarification of definitions, and modified national institutes of health activity and chronicity indices. Kidney Int 2018; 93(4): 789–796.
Google Scholar | Crossref | Medline35. Giannelou, M, Mavragani, CP. Cardiovascular disease in systemic lupus erythematosus: a comprehensive update. J Autoimmun 2017; 82: 1–12.
Google Scholar | Crossref | Medline